A novel antibody–drug conjugate targeting ROR2 (CAB-ROR2-ADC) is currently in a Phase I/II study [57]Given the known roles of ROR2 in phenotype switching and invasion in melanoma [28, 58, 59] and the data we present here revealing a role in VEGF secretion in BRAFV600E melanomas, we propose that the WNT-ROR2 axis represents an attractive treatment target in patients with BRAF mutant melanoma. Here, VEGFA is linked to melanoma.